Resultado de búsqueda
19 de jun. de 2020 · KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the completion of the acquisition of Themis, a privately-held company focused on vaccines and immune-modulation therapies for infectious diseases and cancer.
26 de may. de 2020 · Themis is developing immunomodulation therapies for infectious diseases and cancer. Through advanced understanding of immune system mechanisms, the company has built a sophisticated and versatile technology platform for the discovery, development and production of vaccines as well as other immune system activation approaches.
Themis Bioscience is said to have a pipeline of vaccine candidates and immune-modulatory therapies, which have been developed using its measles virus vector platform. In March 2020, the Austrian vaccine maker joined a consortium alongside France-based Institut Pasteur and The Center for Vaccine Research at the University of Pittsburgh for ...
19 de nov. de 2014 · About Themis: Themis Bioscience GmbH develops prophylactic vaccines from the preclinical to the early clinical phase, focusing on emerging tropical infectious diseases, with initial vaccine candidates currently being developed against Chikungunya and Dengue.
26 de may. de 2020 · KENILWORTH, N.J.-- ( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Themis, a company focused on vaccines and immune-modulation therapies for...
Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The Company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases.
26 de feb. de 2019 · By Angus Liu Feb 26, 2019 11:57am. vaccine development Chikungunya Emergent BioSolutions PaxVax. After turning up positive phase 2 data late last year, Themis Bioscience’ chikungunya vaccine...
